-- 根據週一提交給澳洲證券交易所的文件顯示，Chrysos（ASX：C79）今年迄今已簽署19份新的PhotonAssay租賃協議，該公司計劃在2027財年加速部署這項礦業樣品分析技術。 該公司維持了其2026財年的業績預期，稱營收正朝著8000萬至9000萬澳元預測區間的上限穩步邁進，息稅折舊攤銷前利潤（EBITDA）也有望達到2000萬至2700萬澳元預期區間的上限。 週一，Chrysos股價上漲1%。
Related Articles
Research
Research Alert: CFRA Retains Buy Rating On Shares Of Stryker Corporation
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our target price to $360 from $438, 21.5x our 2027 EPS forecast, below SYK's 10-year historical average of 24.5x. We maintain our 2026 EPS forecast at $14.94 and our 2027 EPS estimate at $16.71. We think that Stryker's Q1 results were significantly impacted by the late-quarter cyber incident that caused global business disruptions, leading to a miss on both revenue and earnings estimates. Despite disruptions affecting manufacturing, shipments, and revenue recognition, management maintained the full-year 2026 guidance of 8% to 9.5% Y/Y organic sales growth and adjusted EPS in the range of $14.90 to $15.10, expecting to recover most lost sales, which we find encouraging. Key catalysts for the remainder of the year include the proposed acquisition of Amplitude Vascular Systems, which has the potential to expand Stryker's cardiovascular capabilities and the creation of a new Ortho Tech business, which could streamline innovation and customer experience, in our view.
$SYK
International
Philippine Manufacturing Activity Contracts as Orders Fall, Costs Rise, S&P Global Says
The Philippines' manufacturing sector slipped into contraction in April as new orders fell sharply and cost pressures intensified, according to data released Monday by S&P Global.The S&P Global Philippines Manufacturing Purchasing Managers' Index fell to 48.3 in April from 51.3 in March, marking the first contraction since November.New orders declined at the fastest pace since August 2021, while export demand weakened further, with firms citing trade route disruptions and halted shipments.Production stalled, and firms cut employment and purchasing activity, drawing down inventories to meet output needs.Input costs rose at the fastest pace since December 2022, driven by higher energy and shipping costs linked to the Middle East war, prompting the sharpest increase in selling prices in 41 months.Supplier delivery times lengthened, while business confidence improved to a 17-month high on expectations of stronger demand ahead.
$^PSEi
Research
Research Alert: CFRA Maintains Hold View On Shares Of Ametek, Inc.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Following AME's Q1 beat, we lift our 12-month target to $260 from $240, valuing shares at 29.5x our 2027 EPS outlook of $8.81 (up $0.20; 2026 EPS outlook lifted to $8.12 from $8.00), above AME's five-year historical multiple average given a strengthening earnings growth trajectory. Notably, AME experienced a Q1 acceleration in demand, highlighted by record orders of $2.2 billion, representing 22% organic growth and leading to a record backlog of $3.87 billion. This growth was broad-based, with sustained strength in Aerospace & Defense and a notable inflection in orders for the more cyclical Process and Power businesses. Profitability also was a positive, as core operating margins expanded by 160 basis points, driven by volume leverage in the Electromechanical Group (EMG). Overall, Q1 results were encouraging though shipment delays stemming from conflict in the Middle East was a modest headwind, indicating that spillover effects could become a bigger headache if instability in the region worsens.
$AME